Efficacy and safety of deuremidevir hydrobromide in treatment of patients with mild and moderate COVID-19
Objective To investigate the efficacy and safety of deuremidevir hydrobromide in the treatment of patients with mild and moderate corona virus disease 2019(COVID-19).Methods A total of 242 patients with mild and moderate COVID-19 admitted to Shengzhou Hospital of Traditional Chinese Medicine between May 8,2023 and August 5,2023 were enrolled,including 169 cases treated with deuremidevir hydrobromide(study group)and 73 cases did not receive any antiviral treatment(control group).Demographic data,underlying diseases,first positive nucleic acid test time and Ct value,disease severity,adverse drug reactions,time of nucleic acid test negative conversion(viral clearance time)and clinical recovery time,and progression to severe disease were compared between two groups.The viral clearance and clinical recovery time were calculated by Kaplan-Meier analysis,and the hazard ratio(HR)and 95％CIof each variate were calculated by multivariate Cox regression.Results Among 242 patients,there were 134 mild cases(55.4％)and 108 mo-derate cases(44.6％);and 232 cases(95.9％)had risk factors of progression to severe/critical disease,including 179 cases of cardiovascular and cerebrovascular diseases(74.0％),77 cases of diabetes(31.8％),and 42 cases of chronic pulmonary diseases(17.4％).Patients in the study group had average older ages and higher proportion of chronic lung disease(both P＜0.05).The viral clearance time and clinical recovery time in the study group were significantly shorter than those in the control group(both P＜0.05).Multivariate Cox regression analysis showed that the HR of viral clearance time was 2.93(95％CI:2.13-4.02),and the HR of clinical recovery time was 3.63(95％CI:2.59-5.11),both P＜0.01.During the hospitalization 5 cases(3.0％)in the study group and 2 cases(2.7％)in the control group progressed to severe cases(P＞0.05).Adverse reactions were observed in 9 cases(5.3％)of the study group,but there were no cases of serious adverse reactions.Conclusion Deuremidevir hydrobromide is effective in treatment of mild and moderate COVID-19,which can significantly shorten viral clearance time and clinical recovery time of patients,and has good safety.
Deuremidevir hydrobromideCorona virus disease 2019Viral clearanceClinical recoveryAdverse drug reactions
万方数据
维普
